Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

SQI Diagnostics Inc V.SQD.H

SQI Diagnostics Inc. is a Canada-based company that is focused on lung health. The Company is engaged in the development and manufacturing of respiratory health and precision medicine tests that run on its fully automated systems. Its clinical solutions include Rapid Acute Lung Injury Diagnostic (RALI-Dx), lung transplant diagnostics, COVID-19 testing and surveillance testing solutions. Its RALI-Dx IL-6 Severity Triage Test and the RALI-fast IL-6 Severity Triage point of care (POC) Test each help clinicians identify which patients with SARS-CoV-2 are predicted to have a severe inflammatory response and should or should not be admitted to the hospital. Its RALI-Dx delivers results from the lab in less than an hour while RALI-fast delivers results at the patient point-of-care in about 15 minutes. The Company’s TORdx LUNG Test measures inflammation at the molecular level to assess the health of the donor lung. The Company is also focused on its organ transplant pipeline of products.


TSXV:SQD.H - Post by User

Comment by 25Stone7859on Mar 08, 2023 1:13pm
104 Views
Post# 35326215

RE:Never any doubt - Just time - HUGE incentives

RE:Never any doubt - Just time - HUGE incentivesHey FF, this PR is more than two years old. It must be irrelevant by now. Since you know the Matthews, could you ask them  why HC and FDA submissions were never submitted even though TOR-dx validation was completed in Jan/2020? The SQI problem is lack of money. That is what should be discussed in these posts, not the products themselves that are undeniably important. Bringing up historical data from 2012 ,2018 and 2020 is just like speaking to the converted.  As a reminder, there is the possibility of a dark event occurence such as bankruptcy that is looming. As such, and hypothetically, Pivot and the three big Insiders as a whole could each claim 50% off the assets and either sell them off or restart the operation anew, possibly through an IPO or some such. But no one knows what is next.  The huge question everyone is asking is why the BoD and AM have not been able to fix this, even though the pipeline is so attractive. No one is biting. Yet these individuals have been so supportive over the years  and that cannot be denied, so it a surprise.There seems to be a big impediment somewhere in the mix that is turning off potential white knights.
SQI's track record to date has not been exemplary. Remember the BIG PHARMA experiment and even the recent PBI acquisition which is almost a negative with the latest Q1 results. So maybe SQI @ $0.045 is realistic given the disappointment and circumstances so far.
<< Previous
Bullboard Posts
Next >>